Abcam, ab133032, Urinary Prostacyclin ELISA kit

Size: 1 x 96Tests
Urinary Prostacyclin ELISA kit is a Competitive ELISA for the measurement of Urinary Prostacyclin in Human in Biofluids, Cell Culture Media samples.
Key facts
Detection method:Colorimetric,
Sample types:Urine, Cell culture supernatant, Tissue Culture Media,
Reacts with:Human,
Assay type:Competitive,
Sensitivity:= 6.58 pg/mL,
Range:7.81 - 2000 pg/mL,
Assay time:3h,
Assay Platform:Microplate

Product details:
Abcam's Human Urinary Prostacyclin
in vitro
competitive ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the accurate quantitative measurement of Prostacyclin breakdown products in urine. The kit measures the two major breakdown products of Prostacyclin in urine, 6-keto-Prostaglandin F
alpha (6k-PGF
alpha) and 2,3-dinor-6-keto-Prostaglandin F
alpha (2,3d-6k-PGF
alpha).
A donkey anti-sheep IgG antibody has been precoated onto 96-well plates. Standards or test samples are added to the wells, along with an alkaline phosphatase (AP) conjugated- Urinary Prostacyclin antigen and a polyclonal sheep antibody specific to Urinary Prostacyclin. After incubation the excess reagents are washed away. pNpp substrate is added and after a short incubation the enzyme reaction is stopped and the yellow color generated is read at 405 nm. The intensity of the yellow coloration is inversely proportional to the amount of Urinary Prostacyclin captured in the plate.
Prostacyclin (PGI
) is involved in platelet aggregation, vasoconstriction, and reproductive functions. PGI
has a half life of 60 minutes in plasma but only 2 to 3 minutes in buffer. The production of PGI
is typically monitored by measurement of 6k-PGF
and 2,3d-6k- PGF
. 6-keto- PGF
is produced by the non-enzymatic hydration of PGI
, and is further metabolized in urine to the 2,3-dinor derivative. A number of pharmaceuticals alter and/or inhibit the synthesis of PGI
. Methods to measure PGI
in urine typically involve HPLC, gas chromatography/mass spectrometry, or radioimmunoassay and enzyme immunoassay for 6k- PGF
Cross Reactivity
The cross reactivity for a number of related eicosanoid compounds was determined.
Compound
Cross Reactivity
2,3-dinor-6-keto-PGF
6-keto-PGF
89.14%
13.21%
13,14 dihydro-PGF
15-keto-PGF
6,15-diketo-13,14 dihydro-PGF

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Prostacyclin also known as PGI2 is a member of the prostaglandin family and functions primarily as a vasodilator and inhibitor of platelet aggregation. This compound is synthesized by the enzyme prostacyclin synthase which has a molecular weight of approximately 50 kDa. Prostacyclin is expressed in endothelial cells lining the blood vessels and is quickly released upon synthesis to exert its effects on smooth muscle cells and platelets.
Biological function summary
Prostacyclin plays important roles in vascular homeostasis and hemostasis. It works by increasing cyclic adenosine monophosphate (cAMP) levels in the target cells leading to smooth muscle relaxation and reduced platelet activation. It is not a part of a traditional protein complex but its actions are tightly regulated through interactions with its receptor the prostacyclin receptor (IP receptor) on target cells.
Pathways
Prostacyclin is an integral element of the arachidonic acid pathway which is key in inflammation and thrombosis. It is synthesized from prostaglandin H2 (PGH2) by the action of prostacyclin synthase. This pathway also includes other prostaglandins such as thromboxane A2 which counteracts the effects of prostacyclin by promoting platelet aggregation and vasoconstriction. These prostaglandins work in tandem to maintain vascular balance.
Prostacyclin is implicated in cardiovascular diseases particularly in the pathophysiology of pulmonary hypertension where its vasodilatory properties are beneficial. Loss of prostacyclin production is observed in conditions such as atherosclerosis leading to increased risk of thrombosis and vessel constriction. Related proteins including thromboxane A2 are often studied alongside prostacyclin to understand the balance between vasodilation and vasoconstriction in cardiovascular health.